Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives

Gynecological Endocrinology

Volumn 32, Issue 6, 2016, Pages 431-438

  Paul, Cristiana ^a   Laganà, Antonio Simone ^b   Maniglio, Paolo ^c   Triolo, Onofrio ^b   Brady, David M ^d  

^a Independent Researcher and Consultant   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BRIDGEPORT   (United States)

Author keywords

Diabetes; insulin; insulin resistance; insulin sensitizer; polycystic ovary syndrome

Indexed keywords

ACETYLCYSTEINE; GLUCOSE; INOSITOL; INSULIN SENSITIZING AGENT; THIOCTIC ACID; VITAMIN B COMPLEX;

HUMAN; INSULIN RESISTANCE; MENSTRUAL CYCLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; STEREOISOMERISM; URINARY EXCRETION; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; FEMALE; META ANALYSIS; POLYCYSTIC OVARY SYNDROME;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INOSITOL; INSULIN RESISTANCE; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; VITAMIN B COMPLEX;

EID: 84961200223     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2016.1144741     Document Type: Review

References (72)

1. A.D.Genazzani, A.Prati, S.Santagni,. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012; 28: 969– 73
2. R.S.Legro Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 99– 109
3. T.Sir-Petermann, B.Angel, M.Maliqueo,. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002; 45: 959– 64
4. K.F.Petersen, G.I.Shulman Etiology of insulin resistance. Am J Med 2006; 119: S10– 6
5. A.Erol Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress. Bioessays 2007; 29: 811– 18
6. M.G.Watve, C.S.Yajnik Evolutionary origins of insulin resistance: a behavioral switch hypothesis. BMC Evol Biol 2007; 7: 61
7. G.M.Reaven Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595– 607
8. C.Paul, D.M.Brady Inositol modulation of essential metabolic pathways of insulin resistance in metabolic syndrome, polycystic ovarian syndrome, and type 2 diabetes. Townsend Lett 2015;August/Sep: 101– 8
9. G.M.Reaven The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51: 931– 8
10. G.M.Reaven The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83: 1237– 47
11. V.T.Samuel, G.I.Shulman Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148: 852– 71
12. J.Ye Mechanisms of insulin resistance in obesity. Front Med 2013; 7: 14– 24
13. R.Parikh, V.Mohan Changing definitions of metabolic syndrome. Indian J Endocrinol Metab 2012; 16: 7– 12
14. S.Gerli, M.Mignosa, G.C.Di Renzo Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003; 7: 151– 9
15. G.Di Paolo, P.De Camilli Phosphoinositides in cell regulation and membrane dynamics. Nature 2006; 443: 651– 7
16. R.Isabella, E.Raffone Does ovary need d-chiro-inositol? J Ovarian Res 2012; 5: 14
17. J.Larner D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3: 47– 60
18. M.L.Croze, C.O.Soulage Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 2013; 95: 1811– 27
19. J.P.Baillargeon, E.Diamanti-Kandarakis, R.E.Ostlund,. Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29: 300– 5
20. J.M.Kawa, R.Przybylski, C.G.Taylor Urinary chiro-inositol and myo-inositol excretion is elevated in the diabetic db/db mouse and streptozotocin diabetic rat. Exp Biol Med (Maywood) 2003; 228: 907– 14
21. W.W.Campbell, R.E.Ostlund, L.J.Joseph,. Relationships of plasma C-peptide and gender to the urinary excretion of inositols in older people. Horm Metab Res 2001; 33: 44– 51
22. V.Unfer, G.Porcaro Updates on the myo-inositol plus d-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 2014; 7: 623– 31
23. A.D.Genazzani, C.Lanzoni, F.Ricchieri, V.M.Jasonni Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 139– 44
24. P.G.Artini, O.M.Di Berardino, F.Papini,. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013; 29: 375– 9
25. R.Venturella, R.Mocciaro, E.De Trana,. Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol 2012; 64: 239– 43
26. E.Papaleo, V.Unfer, J.-P.Baillargeon,. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700– 3
27. V.Unfer, G.Carlomagno, G.Dante, F.Facchinetti Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28: 509– 15
28. E.Papaleo, V.Unfer, J.P.Baillargeon,. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91: 1750– 4
29. T.T.Y.Chiu, M.S.Rogers, E.L.K.Law,. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002; 17: 1591– 6
30. V.Unfer, G.Carlomagno, P.Rizzo,. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011; 15: 452– 7
31. L.Ciotta, M.Stracquadanio, I.Pagano,. Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome. Minerva Ginecol 2010; 62: 525– 31
32. R.D'Anna, A.Scilipoti, D.Giordano,. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 2013; 36: 854– 7
33. B.Matarrelli, E.Vitacolonna, M.D’Angelo,. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 2013; 26: 967– 72
34. R.D’Anna, V.Di Benedetto, P.Rizzo,. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012; 28: 440– 2
35. M.Noventa, A.Vitagliano, M.Quaranta,. Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: a summary of evidences and future applications. Reprod Sci 2015;pii: 1933719115594018 [Epub ahead of print]
36. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19– 25
37. A.Vitagliano, M.Quaranta, M.Noventa, S.Gizzo “Empiric” inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet 2015; 291: 955– 7
38. R.Azziz, K.S.Woods, R.Reyna,. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745– 9
39. R.J.Norman, D.Dewailly, R.S.Legro, T.E.Hickey Polycystic ovary syndrome. Lancet 2007; 370: 685– 97
40. A.Vitagliano, M.Noventa, S.Gizzo Is it time to consider patients suffering from endometriosis-related infertility as “novel candidates” for targeted peri-conceptional d-chiro inositol supplementation? Hypothesis, rationale, and some considerations. J Assist Reprod Genet 2015; 32: 407– 8
41. A.Pizzo, A.S.Laganà, L.Barbaro Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 2014; 30: 205– 8
42. A.S.Laganà, A.Pizzo Authors’ reply to: “Empiric” inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet 2015; 291: 959– 60
43. D.W.Stovall, A.P.Bailey, L.M.Pastore Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011; 20: 37– 43
44. J.J.Conn, H.S.Jacobs, G.S.Conway The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000; 52: 81– 6
45. P.F.Svendsen, S.Madsbad, L.Nilas The insulin-resistant phenotype of polycystic ovary syndrome. Fertil Steril 2010; 94: 1052– 8
46. J.E.Nestler, D.J.Jakubowicz, P.Reamer,. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314– 20
47. M.J.Iuorno, D.J.Jakubowicz, J.-P.Baillargeon,. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8: 417– 23
48. S.Gerli, E.Papaleo, A.Ferrari, G.Di Renzo Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007; 11: 347– 54
49. D.Costantino, G.Minozzi, E.Minozzi, C.Guaraldi Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009; 13: 105– 10
50. M.Nordio, E.Proietti The combined therapy with myo-inositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012; 16: 575– 81
51. M.Minozzi, M.Nordio, R.Pajalich The combined therapy myo-inositol plus d-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 2013; 17: 537– 40
52. A.S.Laganà, L.Barbaro, A.Pizzo Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-chiro-inositol. Arch Gynecol Obstet 2015; 291: 1181– 6
53. A.D.Genazzani, S.Santagni, E.Rattighieri,. Modulatory role of d-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014; 30: 438– 43
54. A.Sacchinelli, R.Venturella, D.Lico,. The efficacy of inositol and n-acetyl cysteine administration (ovaric HP) in improving the ovarian function in infertile women with PCOS with or without insulin resistance. Obstet Gynecol Int 2014; 2014: 141020
55. A.S.Laganà, A.Pizzo Know your enemy: the rationale of using inositol in the treatment of polycystic ovary syndrome. Endocrinol Metab Syndr 2013; 02: 2– 3
56. A.Bevilacqua, G.Carlomagno, S.Gerli,. Results from the international consensus conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology–assisted reproduction technology. Gynecol Endocrinol 2015; 31: 441– 6
57. S.Colazingari, M.Treglia, R.Najjar, A.Bevilacqua The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 2013; 288: 1405– 11
58. D.Giordano, F.Corrado, A.Santamaria,. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 2011; 18: 102– 4
59. A.Santamaria, D.Giordano, F.Corrado,. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric 2012; 15: 490– 5
60. I.Capasso, E.Esposito, N.Maurea,. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials 2013; 14: 273. doi: 10.1186/1745-6215-14-273
61. A.Malvasi, F.Casciaro, M.M.Minervini,. D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci 2014; 18: 270– 4
62. J.L.Evans, I.D.Goldfine Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000; 2: 401– 13
63. H.Ansar, Z.Mazloom, F.Kazemi, N.Hejazi Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J 2011; 32: 584– 8
64. M.M.Zacchè, L.Caputo, S.Filippis,. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 508– 13
65. A.D.Genazzani, G.Despini, S.Santagni,. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Synd 2014; 3: 140. doi: 10.4172/2161-1017.1000140
66. A.Cianci, M.Panella, M.Fichera,. d-chiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol Endocrinol 2015; 31: 483– 6
67. M.Le Donne, A.Alibrandi, R.Giarrusso,. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Minerva Ginecol 2012; 64: 23– 9
68. E.Raffone, P.Rizzo, V.Benedetto Insulin sensitizer agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010; 26: 275– 80
69. V.Cappelli, A.Di Sabatino, M.C.Musacchio, V.De Leo Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS. Minerva Ginecol 2013; 65: 425– 33
70. G.Oner, I.I.Muderri Clinical, endocrine, and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2010; 159: 127– 31
71. M.Minozzi, D.Costantino, C.Guaraldi, V.Unfer The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011; 27: 920– 4
72. Z.Kamenov, G.Kolarov, A.Gateva,. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 2015; 31: 131– 5